Couttenye MM - Search Results

1

Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation.

Ledeganck KJ, De Winter BY, Van den Driessche A, Jürgens A, Bosmans JL, Couttenye MM, Verpooten GA. Ledeganck KJ, et al. Among authors: couttenye mm. Nephrol Dial Transplant. 2014 May;29(5):1097-102. doi: 10.1093/ndt/gft498. Epub 2013 Dec 18. Nephrol Dial Transplant. 2014. PMID: 24353324

2

Functional acute renal failure in a patient with carcinoid syndrome.

Couttenye MM, Verpooten GA, Daelemans RA, De Broe ME. Couttenye MM, et al. Nephron. 1987;47(2):131-3. doi: 10.1159/000184475. Nephron. 1987. PMID: 3696318

3

New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients.

De Broe ME, D'Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. De Broe ME, et al. Among authors: couttenye mm. Nephrol Dial Transplant. 1993;8 Suppl 1:47-50. doi: 10.1093/ndt/8.supp1.47. Nephrol Dial Transplant. 1993. PMID: 8389021 No abstract available.

4

Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients.

Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Lefebure AF, et al. Among authors: couttenye mm. Vaccine. 1993;11(4):397-9. doi: 10.1016/0264-410x(93)90278-6. Vaccine. 1993. PMID: 8470423 Clinical Trial.

5

Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.

D'Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME. D'Haese PC, et al. Among authors: couttenye mm. Nephrol Dial Transplant. 1995 Oct;10(10):1874-84. Nephrol Dial Transplant. 1995. PMID: 8592597 Clinical Trial.

6

Determination of ionized calcium: evaluation of sampling and storage procedures.

Couttenye MM, Jurgens A, Lamberts LV, Verpooten GA, D'Haese PC, De Broe ME. Couttenye MM, et al. Clin Chem. 1996 Mar;42(3):468-9. Clin Chem. 1996. PMID: 8598117 No abstract available.

7

Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.

Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME. Couttenye MM, et al. Nephrol Dial Transplant. 1996 Jun;11(6):1065-72. Nephrol Dial Transplant. 1996. PMID: 8671970

8

Is there a link between erythropoietin therapy and adynamic bone disease?

Smans KA, Van Landeghem FG, D'Haese PC, Couttenye MM, De Broe ME. Smans KA, et al. Among authors: couttenye mm. Nephrol Dial Transplant. 1996 Jul;11(7):1248-9. Nephrol Dial Transplant. 1996. PMID: 8672017 Review. No abstract available.

9

Diagnosis and treatment of aluminium bone disease.

D'Haese PC, Couttenye MM, De Broe ME. D'Haese PC, et al. Among authors: couttenye mm. Nephrol Dial Transplant. 1996;11 Suppl 3:74-9. doi: 10.1093/ndt/11.supp3.74. Nephrol Dial Transplant. 1996. PMID: 8840316 Review.

10

High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population.

Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. Couttenye MM, et al. Nephrol Dial Transplant. 1997 Oct;12(10):2144-50. doi: 10.1093/ndt/12.10.2144. Nephrol Dial Transplant. 1997. PMID: 9351080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page